Evidence map›Paper›PMID 42344727›Full record

ArticleFrontiers in microbiology2026

Shahebraj Khan, Duc Nguyen, Dejan Nikolic, Baojie Wan, Akil Hossain, Mallique Qader, Sanghyun Cho, Scott G Franzblau, Gauri S Shetye

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shahebraj KhanDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Duc NguyenDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Dejan NikolicDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Baojie WanDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Akil HossainDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Mallique QaderDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Sanghyun ChoDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Scott G FranzblauDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.
Gauri S ShetyeDepartment of Pharmaceutical Sciences, Retzky College of Pharmacy, Institute for Tuberculosis Research, University of Illinois Chicago, Chicago, IL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bedaquiline (B), pretomanid (Pa), and linezolid (L) (BPaL) regimen is highly effective for drug-resistant tuberculosis (TB) but is limited by linezolid-associated toxicities, including myelosuppression and peripheral neuropathy. We evaluated omadacycline as a representative tetracycline-class protein synthesis inhibitor (PSI) to assess whether it can contribute functional activity within a BPa backbone. Omadacycline exhibited a minimum inhibitory concentration (MIC) of 2-4 μg/mL against

Indexed as

bedaquilinelinezolidMycobacterium tuberculosisomadacyclinepretomanidprotein synthesis inhibitorsTB relapse mice modeltetracyclines

Identifiers

PMID42344727
PMCPMC13287072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.